Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | S100B | P04271 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HPD | P32754 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12314599 | 0.73 | MAPT (0.50) | ATAD2S100BTSHRALDH1A1MEN1 | |
| SCHEMBL1115708 | 0.66 | MAPT (0.62) | ALDH1A1KMT2AKDM4EGAAMAPT | |
| SCHEMBL30904741 | 0.64 | BCL6 (0.45) | ATAD2S100BBCL6 | |
| SCHEMBL20569764 | 0.64 | BCL6 (0.45) | ATAD2S100BBCL6 | |
| SCHEMBL19511949 | 0.64 | PTK2 (0.35) | — | |
| SCHEMBL16771511 | 0.63 | ATAD2 (1.00) | ATAD2S100BTSHRALDH1A1KMT2A | |
| SCHEMBL6745385 | 0.63 | ATAD2 (0.64) | ATAD2S100BALDH1A1MEN1KMT2A | |
| SCHEMBL19511700 | 0.62 | PTK2 (0.41) | — | |
| SCHEMBL10145941 | 0.61 | GRM2 (0.47) | TSHRHPDALDH1A1MEN1KMT2A | |
| SCHEMBL16736495 | 0.61 | ATAD2 (0.62) | ATAD2S100BALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8262949-B2 | Long wavelength shifted benzotriazole uv-absorbers and their use | BASF SE (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20100163813-A1 | Long wavelength shifted benzotriazole uv-absorbers and their use | CIBA CORPORATION | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100163813-A1 | Long wavelength shifted benzotriazole uv-absorbers and their use | SULT1A1, GABBR1, TPMT | ATAD2 1998/4885S100B 792/4885TSHR 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.